Ocular Therapeutix

Punctal plug drug delivery attractive method for managing glaucomaPunctal plug-based delivery systems for sustained delivery of glaucoma medications represent new and versatile technology that is under development. The hope is it can help with the problem of patient compliance when managing mild-moderate glaucoma, said Marlene Moster, MD.
Applying hydrogel technology to sustained-release ocular drugsHydrogel technology enables the use of drugs that are known to be efficacious for ocular diseases and conditions when formulated as daily drops or monthly injections, into one-time or several-month dosage forms.
Anti-angiogenic agent, platform planned for human trialFindings from preclinical studies show that a novel intravitreal depot of an anti-angiogenic drug releases the medication over a period of at least 6 months, is well-tolerated, and prevents VEGF-induced retinal vascular leakage.
New technologies on horizon to redefine drug deliveryGlaucoma has an adherence problem. Drugs that are highly efficacious are far less than optimally effective because patients fail to take eye drops properly or don’t take them all. Novel drug-delivery technologies could improve adherence and outcomes.
How to combat vernal keratoconjunctivitisIt is a precarious position considering the desire to find the perfect remedy— yet with vernal keratoconjunctivitis (VKC), there is no magic bullet.
Drug therapies, delivery systems advance for glaucoma carePharmacologic products and devices in development continue to gain momentum in the glaucoma treatment armamentarium.
Drug-loaded plug eases adherence issues for patients, physiciansResults of two phase III trials with dexamethasone intracanalicular depot are highlighted. Both trials met the endpoints for postsurgical pain, but only one trial met the endpoints for postoperative inflammation
Drug-delivery platforms offer more options and promise for cliniciansSeven glaucoma drug delivery companies reviewed the latest data on platforms
Intracanalicular drug depot may fill unmet need for better topical therapyA sustained-release dexamethasone intracanalicular depot may be able to treat post-cataract surgery inflammation without causing spikes in IOP. The product’s one-time administration may also improve compliance and convenience.
What punctal plug delivery of dexamethasone means for allergic conjunctivitisTreatment of chronic allergic conjunctivitis with a sustained-release dexamethasone resulted in better clinical results because of the sustained and controlled delivery.